Literature DB >> 1482641

The effect of erythropoietin on the cellular defence mechanism of red blood cells in children with chronic renal failure.

S Túri1, I Németh, I Varga, T Bodrogi, B Matkovics.   

Abstract

The glutathione redox system, haemoglobin (Hb) oxidation, the activity of antioxidant enzymes and the lipid peroxidation product malonyl dialdehyde (MDA) were studied in red blood cells (RBCs) during administration of recombinant human erythropoietin (rhEPO) over 12 weeks in ten children maintained on haemodialysis. A rapid increase in the reticulocyte count was accompanied by a slower rise in total Hb concentration. The mean level of oxidized glutathione (GSSG) increased from 13.2 +/- 5.3 nmol/g Hb to 56.7 +/- 15.8 nmol/g Hb 4 weeks after the start of rhEPO (P < 0.001), followed by a fall to the basal value. Reduced glutathione (GSH) levels showed a smaller though constant elevation during rhEPO therapy (P < 0.001). Before rhEPO treatment, incubation of RBCs for 1 h with acetylphenylhydrazine induced a decrease in GSH concentration compared with controls (P < 0.001), which became more pronounced in the first few weeks of rhEPO therapy (P < 0.001). In addition, the percentage of Hb derivatives (metHb and haemichrome) increased in the first 4 weeks of rhEPO therapy (P < 0.001). Although there was no significant difference between the values obtained preEPO and during EPO treatment, MDA levels were continuously higher and superoxide dismutase, catalase and glutathione peroxidase concentrations were lower than in the controls (P < 0.001). These results are compatible with oxidative damage to the RBCs in the early period of rhEPO therapy in children with end-stage renal failure. The GSH-GSSG system, as an important cellular defence mechanism of the RBCs, appears to be severely affected.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1482641     DOI: 10.1007/bf00866497

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  37 in total

1.  The glutathione instability of drug-sensitive red cells; a new method for the in vitro detection of drug sensitivity.

Authors:  E BEUTLER
Journal:  J Lab Clin Med       Date:  1957-01

2.  Hemoglobin conversion to hemichrome under the influence of fatty acids.

Authors:  A A Akhrem; G M Andreyuk; M A Kisel; P A Kiselev
Journal:  Biochim Biophys Acta       Date:  1989-08-18

3.  Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent.

Authors:  J Sedlak; R H Lindsay
Journal:  Anal Biochem       Date:  1968-10-24       Impact factor: 3.365

4.  The effect of malonyldialdehyde on erythrocyte deformability.

Authors:  C Pfafferott; H J Meiselman; P Hochstein
Journal:  Blood       Date:  1982-01       Impact factor: 22.113

5.  Recombinant human erythropoietin therapy in haemodialysis patients--dose determination and clinical experience.

Authors:  J Bommer; C Alexiou; U Müller-Bühl; J Eifert; E Ritz
Journal:  Nephrol Dial Transplant       Date:  1987       Impact factor: 5.992

6.  Oxidative interactions between haemoglobin and membrane lipid. A liposome model.

Authors:  J Szebeni; C C Winterbourn; R W Carrell
Journal:  Biochem J       Date:  1984-06-15       Impact factor: 3.857

7.  Glutathione, glutathione reductase and glutathione S-transferase activities in erythrocytes and lymphocytes in chronic renal disease.

Authors:  F H El-Rashidy; W A Al-Turk; S J Stohs
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1984-06

8.  Use of subcutaneous recombinant human erythropoietin in children undergoing continuous cycling peritoneal dialysis.

Authors:  L Sinai-Trieman; I B Salusky; R N Fine
Journal:  J Pediatr       Date:  1989-04       Impact factor: 4.406

9.  Recombinant human erythropoietin in patients with anemia due to end-stage renal disease. US multicenter trials.

Authors:  J T Sobota
Journal:  Contrib Nephrol       Date:  1989       Impact factor: 1.580

10.  Dose-finding, double-blind, clinical trial of recombinant human erythropoietin (Chugai) in Japanese patients with end-stage renal disease. Research Group for Clinical Assessment of rhEPO.

Authors:  M Suzuki; Y Hirasawa; K Hirashima; M Arakawa; M Odaka; Y Ogura; Y Yoshikawa; T Sanaka; A Shinoda; H Morii
Journal:  Contrib Nephrol       Date:  1989       Impact factor: 1.580

View more
  5 in total

1.  Different administration schedules of darbepoetin alfa affect oxidized and reduced glutathione levels to a similar extent in 5/6 nephrectomized rats.

Authors:  Péter Monostori; Gabriella F Kocsis; Zsuzsanna Ökrös; Péter Bencsik; Orsolya Czétényi; Zoltán Kiss; Balázs Gellén; Csaba Bereczki; Imre Ocsovszki; Judit Pipis; János Pálóczi; Márta Sárközy; Szilvia Török; Ilona S Varga; István Kiss; Eszter Fodor; Tamás Csont; Péter Ferdinandy; Sándor Túri
Journal:  Clin Exp Nephrol       Date:  2012-12-06       Impact factor: 2.801

2.  Erythropoietin protects the intestine against ischemia/ reperfusion injury in rats.

Authors:  Ensari Guneli; Zahide Cavdar; Huray Islekel; Sulen Sarioglu; Serhat Erbayraktar; Muge Kiray; Selman Sokmen; Osman Yilmaz; Necati Gokmen
Journal:  Mol Med       Date:  2007 Sep-Oct       Impact factor: 6.354

3.  The antioxidant effect of erythropoietin on thalassemic blood cells.

Authors:  Johnny Amer; Mutaz Dana; Eitan Fibach
Journal:  Anemia       Date:  2010-12-21

4.  How the duration period of erythropoietin treatment influences the oxidative status of hemodialysis patients.

Authors:  Zorica M Dimitrijevic; Tatjana P Cvetkovic; Vidojko M Djordjevic; Dusica D Pavlovic; Nikola Z Stefanovic; Ivana R Stojanovic; Goran J Paunovic; Radmila M Velickovic-Radovanovic
Journal:  Int J Med Sci       Date:  2012-10-26       Impact factor: 3.738

Review 5.  The role of erythropoietin as an inhibitor of tissue ischemia.

Authors:  Nikolaos Paschos; Marios G Lykissas; Alexandros E Beris
Journal:  Int J Biol Sci       Date:  2008-06-10       Impact factor: 6.580

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.